Multimodal Imaging Assessment of Chronic Kidney Disease Patients at Different Stages From a Cardio-Renal Interaction Perspective

Condition(s) studied

Investigational drug(s) / intervention(s)

18F PET/MR: Tracer: \^18F FAPI 04 is used in this study. A single intravenous bolus dose of 3.70-4.44 MBq/kg is administered. • Simultaneous PET/MR Acquisition: During PET imaging, cardiac MR (CMR) is performed in the supine position. All images are acquired with ECG gating and respiratory gating, during end expiratory breath holds. 1. Cardiac Morphology and Function (Localization \& Cine):Assess cardiac structure and global/regional function 2. T2 Weighted Fat Suppressed Imaging:Evaluate myocardial edema 3. First Pass Perfusion Imaging:Quantitatively assess the extent and severity of myocardial perfusion defects 4. Late Gadolinium Enhancement (LGE): Detect and quantify myocardial necrosis and fibrosis 5. T1 Mapping (Pre and Post Contrast): Quantify myocardial interstitial fibrosis 6. T2 Mapping (Pre Contrast):Quantify myocardial edema 7. Cardiac PET Imaging:Evaluate myocardial fibrosis characteristics using \^18F FAPI PET data

Study summary

This study is a prospective cohort investigation in which consecutive eligible patients undergo 18F-FAPI PET/MR imaging. Chronic kidney disease (CKD) participants are stratified into two groups:Group I ：CKD stages 1-3（eGFR ≥ 30 mL/min/1.73 m²）,Group II :CKD stages 4-5(eGFR \< 30 mL/min/1.73 m²).

Using 18F-FAPI PET/MR, we will evaluate global cardiac functional impairment and myocardial fibrosis characteristics, and analyze their associations with the degree of renal dysfunction.

Eligibility

Primary outcome measure(s)

• Myocardial fibrosis burden measured by 18F-FAPI PET/MR — At baseline (within 1 week of enrollment)
  Myocardial uptake of 18F-FAPI quantified using SUVmax and SUVmean values from PET imaging.
• Myocardial fibrosis burden measured by 18F-FAPI PET/MR — At baseline (within 1 week of enrollment)
  Native T1 value, ECV, and LGE assessed by cardiac MRI to evaluate myocardial fibrosis

Trial sites (1)

More The Affiliated Hospital of Qingdao University trials in China

Other trials for the same condition